| __timestamp | Celldex Therapeutics, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 241751000 |
| Thursday, January 1, 2015 | 4011000 | 322292000 |
| Friday, January 1, 2016 | 102026000 | 344320000 |
| Sunday, January 1, 2017 | 96171000 | 374644000 |
| Monday, January 1, 2018 | 66449000 | 1820000 |
| Tuesday, January 1, 2019 | 42672000 | 4000000 |
| Wednesday, January 1, 2020 | 42534000 | 12000000 |
| Friday, January 1, 2021 | 3068000 | 11000000 |
| Saturday, January 1, 2022 | 1400000 | 14000000 |
| Sunday, January 1, 2023 | 3008000 | 9133000 |
| Monday, January 1, 2024 | 11215000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the cost of revenue for two prominent players: Ionis Pharmaceuticals, Inc. and Celldex Therapeutics, Inc., from 2014 to 2023. Over this period, Ionis Pharmaceuticals consistently reported higher costs, peaking in 2017 with a staggering 374 million USD, while Celldex's highest was in 2016 at 102 million USD. Notably, Ionis's cost of revenue in 2017 was nearly four times that of Celldex's peak, highlighting its expansive operational scale.
However, both companies experienced significant fluctuations. Celldex saw a dramatic 98% drop from its 2014 figures by 2022, reflecting strategic shifts or operational efficiencies. Meanwhile, Ionis's costs plummeted by 97% from 2017 to 2018, indicating potential restructuring or cost-cutting measures. These insights underscore the dynamic nature of financial management in the biotech sector.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: AbbVie Inc. vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Pfizer Inc. and Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.